Amgen Inc. (AMGN)

NASDAQ: AMGN · Real-Time Price · USD
292.00
+0.23 (0.08%)
At close: Oct 30, 2025, 4:00 PM EDT
290.00
-2.00 (-0.68%)
After-hours: Oct 30, 2025, 7:53 PM EDT
0.08%
Market Cap157.20B
Revenue (ttm)34.92B
Net Income (ttm)6.62B
Shares Out 538.36M
EPS (ttm)12.23
PE Ratio23.88
Forward PE14.22
Dividend$9.52 (3.26%)
Ex-Dividend DateAug 22, 2025
Volume2,058,058
Open290.58
Previous Close291.77
Day's Range289.00 - 294.56
52-Week Range253.30 - 335.88
Beta0.48
AnalystsHold
Price Target313.57 (+7.39%)
Earnings DateNov 4, 2025

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Sector Healthcare
Founded 1980
Employees 28,000
Stock Exchange NASDAQ
Ticker Symbol AMGN
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $313.57, which is an increase of 7.39% from the latest price.

Price Target
$313.57
(7.39% upside)
Analyst Consensus: Hold
Stock Forecasts

News

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

THOUSAND OAKS, Calif. , Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of ...

1 day ago - PRNewsWire

These low-risk stocks could be a profitable answer to this volatile earnings season

Slow and steady performers do better over the long term.

Other symbols: BMYCVSGDGISHQYHRLJNJ
7 days ago - Market Watch

Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amgen Inc. (NASDAQ: AMGN) breached their fiduciary duties to shareh...

8 days ago - Business Wire

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.

Other symbols: AZN
13 days ago - Reuters

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif. , Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca ...

13 days ago - PRNewsWire

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.

23 days ago - CNBC

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

24 days ago - Seeking Alpha

Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts

The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.

24 days ago - WSJ

Amgen to sell cholesterol drug at 60% discount direct to US consumers

Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressur...

24 days ago - Reuters

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price  THOUSAND OAKS, Calif. , Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new...

24 days ago - PRNewsWire

October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy

Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net...

Other symbols: AMZNBACRMCSCOCVXDISHON
26 days ago - Seeking Alpha

Cramer's Stop Trading: Amgen

Jim Cramer breaks down why he's keeping an eye on shares of Amgen.

27 days ago - CNBC Television

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK...

4 weeks ago - PRNewsWire

‘Fast Money' traders talk opportunities in health care stocks

The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...

4 weeks ago - CNBC Television

Amgen Shares Cross Above 200 DMA

In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.

4 weeks ago - Forbes

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...

Other symbols: ABBVLLYMRK
4 weeks ago - CNBC Television

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.

Other symbols: ABBVGILDLLYMRKMRNAPFE
4 weeks ago - CNBC Television

AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

4 weeks ago - PRNewsWire

Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition

Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see ...

5 weeks ago - Seeking Alpha

Amgen: Imdelltra Could Be The Next Game Changer

Despite the political noise coming out of the White House over efforts to lower drug prices, Amgen Inc.'s oncology franchise has continued to deliver strong performance since the start of 2025. So, AM...

5 weeks ago - Seeking Alpha

Amgen: Buy The Dip Opportunity

Amgen offers a compelling value and income opportunity after a recent price dip, trading below historical valuation multiples. AMGN posted strong Q2 results with robust performance across its innovati...

6 weeks ago - Seeking Alpha

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...

Other symbols: ABBVAZNGSKNVONVSSNYLLY
7 weeks ago - Reuters

US FDA to step up enforcement of pharma ads, sends enforcement letters

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi...

Other symbols: LLYMRK
7 weeks ago - Reuters

Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amgen Inc. (NASDAQ:AMGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Peter Griffith - Executive VP & CFO Kave Niksefat - Senior Vice Pre...

7 weeks ago - Seeking Alpha

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluati...

7 weeks ago - GlobeNewsWire